- Home
- ZBAI vs TCRX Comparison
ZBAI vs TCRX Comparison
Compare ZBAI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBAI | TCRX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.1M | 63.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZBAI | TCRX |
|---|---|---|
| Price | $7.54 | $1.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 5.9K | ★ 1.1M |
| Earning Date | 06-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.30 | $0.88 |
| 52 Week High | $11.94 | $2.57 |
Technical Indicators
Market Signals| Indicator | ZBAI | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.48 | 76.75 |
| Support Level | $5.86 | $0.93 |
| Resistance Level | $9.56 | $1.96 |
| Average True Range (ATR) | 0.75 | 0.08 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 72.57 | 93.14 |
Price Performance
Historical ComparisonAbout ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.